DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.
DRRX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Durect Corp. To summarize, we found that Durect Corp ranked in the 3th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for DRRX, they are:
Its compound free cash flow growth rate, as measured over the past 2.24 years, is -0.04% -- higher than only 20.04% of stocks in our DCF forecasting set.
As a business, Durect Corp experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than merely 0% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DRRX, try AGHC, AHPI, ALC, AMRN, and DRAD.
DURECT Corporation (DRRX) Q2 2020 Earnings Conference Call August 03, 2020 04:30 PM ET Company Participants Mike Arenberg - Chief Financial Officer Jim Brown - President & Chief Executive Officer WeiQi Lin - Executive Vice President, Research & Development & Principal Scientist Conference Call Participants Ellie Merle - Cantor Fitzgerald...
DURECT Corporation (Nasdaq: DRRX) today announced it has initiated recruiting patients for its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 infected patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of survival and being free of acute organ failure at Day 28. The trial will enroll approximately 80 patients.
DURECT Corporation (Nasdaq: DRRX) today announced that it is set to join the broad-market Russell 3000® Index as a result of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens today, June 29, 2020.